Dosage adjustment for the 3 anti-tumor necrosis factor-α drugs.
| Drug | 6 Months, n = 49 | 12 Months, n = 39 | 24 Months, n = 29 | 36 Months, n = 20 |
|---|---|---|---|---|
| Infliximab, 5 mg/kg | n = 27 | n = 25 | n = 20 | n = 13 |
| Interval between infusions, weeks (SD) | 8.3 (± 1.1) | 8.8 (± 1.5) | 9.4 (± 2.2) | 9.7 (± 2.6) |
| Etanercept | ||||
| Total no. patients | n = 17 | n = 10 | n = 7 | n = 7 |
| Patients taking 25 mg | n = 14 | n = 8 | n = 7 | n = 6 |
| Interval between SC injections, days (SD) | 6.6 (± 0.5) | 7.1 (± 1.3) | 9.0 (± 4.2) | 8.0 (± 3.5) |
| Patients taking 50 mg | n = 3 | n = 2 | No data | n = 1 |
| Interval between SC injections, days (SD) | 12.3 (± 2.5) | 15.0 (± 0.0) | 10.0 | |
| Adalimumab, 40 mg | n = 5 | n = 4 | n = 2 | n = 0 |
| Interval between SC injections, weeks (SD) | 3.1 (± 0.2) | 3.6 (± 0.5) | 3.5 (± 0.7) | No data |
SC: subcutaneous.